Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
about
Mechanisms of drug resistance in kinases.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutationsGamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinomaAcquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaEGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaCovalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment.Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
P2860
Q27692567-07B932DA-1073-4C00-9855-88D1041F348BQ27853162-E31C3572-5C2D-4518-A84A-E4EECA1D28B4Q27853190-1517C6C0-3DB1-4310-8466-2769F6B31DA5Q28655621-06DD7725-FAE5-4234-92F4-B57E6BF0F6B1Q33759715-4E80D01E-5C4C-41D2-B61B-7C44DF5E2BDCQ33992604-FE67A954-9E1D-4AC2-9727-82DEF6BCE4CBQ35081010-99FEC427-AE26-463B-9081-98753669E95CQ35820920-143CB5CA-74CC-4FF2-A21C-4FFDA9D15322Q36916872-4B758BAE-5098-4F25-9E32-903B0858B2B3Q37000611-AA747B94-5558-45E1-9280-5295DD862225Q37206247-C819A755-4645-4C8D-9F2B-A6440A98448BQ37351498-23104AA4-239D-4C19-A996-0EEEEBC3DC03Q37475183-65BD0B8A-1F38-43E9-AD39-BAD6A75A47DDQ39253894-AD69D1E9-91BF-4622-8E02-8381B205516CQ39263992-36962BF6-9C4E-41B7-9095-B14A26B0D2AAQ39819733-B39BA65E-8D29-45D5-94CF-67682A24D6A3Q47146662-26CD2135-A893-4C78-9075-92DA6D7193C0Q55475715-7094A7C1-3DE2-4F50-920E-0D93752D0F84
P2860
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Resistance to an irreversible ...... ls novel treatment strategies.
@en
type
label
Resistance to an irreversible ...... ls novel treatment strategies.
@en
prefLabel
Resistance to an irreversible ...... ls novel treatment strategies.
@en
P2093
P1433
P1476
Resistance to an irreversible ...... ls novel treatment strategies.
@en
P2093
Afshin Dowlati
Balázs Halmos
Daniel G Tenen
Jeffrey A Kern
Patrick C Ma
Susumu Kobayashi
Titus J Boggon
P304
10417-10427
P356
10.1158/0008-5472.CAN-07-1248
P407
P577
2007-11-01T00:00:00Z